Intellia Therapeutics (NTLA): Evaluating Valuation as Analyst Confidence Grows on Pipeline Progress and Revenue Outlook

Intellia Therapeutics (NTLA) is getting renewed attention from investors as analysts underline the company’s pipeline progress and growing revenue. Recent commentary suggests ongoing confidence in their lead program for hereditary angioedema.

See our latest analysis for Intellia Therapeutics.

After a remarkable climb this year, Intellia Therapeutics’ 109% year-to-date share price return has grabbed the spotlight, outpacing most of its biotech peers. While the 1-year total shareholder return sits at 60.5%, the sharp rally in recent months suggests momentum is building again as the market weighs rapid revenue growth against longer-term risks.

If the surge in Intellia’s price has you curious about where the next breakthrough might come from, consider checking out healthcare innovators using our curated screener: See the full list for free.

After such a dramatic rally, is Intellia Therapeutics still trading at a bargain given its pipeline and analyst targets? Or is the market already factoring in all of its future growth prospects?

Most Popular Narrative: 24.9% Undervalued

With Intellia Therapeutics closing at $25.60, the most widely followed narrative estimates fair value at $34.08, implying significant further upside compared to recent trading levels. This perspective is driven by bullish analyst assumptions on future revenue acceleration and margin improvement, as the company’s key clinical programs gain momentum.

The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends, especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE. These factors support higher future patient volumes and underpin potential multi-launch revenue inflection points.

Read the complete narrative.

What hidden numbers are driving this optimistic price target? The boldest earnings forecasts, massive addressable markets, and a future profit profile that could reset sector expectations are all woven into the valuation math. Want to see how these factors stack up and what they mean for Intellia's next chapter? The details may surprise you.

Result: Fair Value of $34.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, competitive advances in gene therapy or unexpected clinical setbacks could challenge Intellia’s path to profitability and potentially disrupt expected long-term growth.

Find out about the key risks to this Intellia Therapeutics narrative.

Another View: SWS DCF Model Paints a Different Picture

While the consensus narrative sees Intellia Therapeutics as undervalued based on projected future profits, our SWS DCF model tells a more cautious story. According to this approach, Intellia’s shares are actually priced above our estimated fair value. This suggests the current rally could be running ahead of fundamentals.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Intellia Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Intellia Therapeutics Narrative

If you think the story looks different through your lens, or want to dig into the numbers yourself, you can easily craft your own perspective in just a few minutes. Do it your way.

A great starting point for your Intellia Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Seize the moment to act on top investment opportunities before the crowd catches on. With the right screener, you could spot tomorrow’s winners today.

• Find market gems poised for big moves by targeting these 876 undervalued stocks based on cash flows with robust cash flows and attractive entry points.
• Unlock steady earning power by focusing on these 17 dividend stocks with yields > 3% that consistently deliver yields over 3% for dependable income.
• Catch the next tech breakout by reviewing these 27 AI penny stocks driving artificial intelligence innovation and shaping tomorrow’s digital world.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com